Literature DB >> 22663776

The effect of a 3-month supervised exercise programme on gait parameters of patients with peripheral arterial disease and intermittent claudication.

Stephanie King1, Natalie Vanicek, Katherine A Mockford, Patrick A Coughlin.   

Abstract

BACKGROUND: The management of peripheral arterial disease with intermittent claudication includes angioplasty, pharmaceutical therapy, risk factor modification and exercise therapy. Supervised exercise programmes are used sporadically but may improve the distance that an individual with claudication can walk. The purpose of this study was to evaluate the effectiveness of a 3-month supervised exercise programme on improving gait parameters in patients with intermittent claudication.
METHODS: 12 participants were recruited (mean (SD) - age: 67.3 (6.8) years, height: 1.67 (0.09) m, mass: 79.4 (14.0) kg, ankle brachial pressure index: 0.73 (0.17)) from the local vascular unit and enrolled in a supervised exercise programme. Kinematic and kinetic data were collected at the following time points: pain-free walking, initial claudication pain, absolute claudication pain and after a patient-defined rest period. Data were collected before and after the 3-month supervised exercise programme.
FINDINGS: No significant differences were found in any of the gait parameters post-intervention including pain-free walking speed (P=0.274), peak hip extension (P=0.125), peak ankle plantarflexion (P=0.254), or first vertical ground reaction force peak (P=0.654). No significant gait differences were found across different levels of pain pre- or post-intervention.
INTERPRETATION: The lack of improvement post-intervention observed suggests that the current exercise protocol was not tailored to elicit significant improvements in patients with intermittent claudication, specifically. The results indicate that exercise programmes may show improved results post-intervention if they are longer in duration and varied in intensity. Further research into more detailed muscle and biomechanical adaptations is needed to inform exercise programmes specific to this population.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22663776     DOI: 10.1016/j.clinbiomech.2012.05.002

Source DB:  PubMed          Journal:  Clin Biomech (Bristol, Avon)        ISSN: 0268-0033            Impact factor:   2.063


  6 in total

1.  Computerized dynamic posturography for postural control assessment in patients with intermittent claudication.

Authors:  Natalie Vanicek; Stephanie A King; Risha Gohil; Ian C Chetter; Patrick A Coughlin
Journal:  J Vis Exp       Date:  2013-12-11       Impact factor: 1.355

2.  Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease.

Authors:  Magdalena Pilz; Elisabeth Kandioler-Honetz; Alfa Wenkstetten-Holub; Waltraud Doerrscheidt; Rudolf Mueller; Robert Wolfgang Kurz
Journal:  Wien Klin Wochenschr       Date:  2014-05-14       Impact factor: 1.704

3.  Changes in Gait Variables in Patients with Intermittent Claudication.

Authors:  Bogdan Pietraszewski; Marek Woźniewski; Ryszard Jasiński; Artur Struzik; Andrzej Szuba
Journal:  Biomed Res Int       Date:  2019-05-27       Impact factor: 3.411

4.  Supervised Exercise Training Improves 6 min Walking Distance and Modifies Gait Pattern during Pain-Free Walking Condition in Patients with Symptomatic Lower Extremity Peripheral Artery Disease.

Authors:  Stefano Lanzi; Joël Boichat; Luca Calanca; Lucia Mazzolai; Davide Malatesta
Journal:  Sensors (Basel)       Date:  2021-11-30       Impact factor: 3.576

Review 5.  Exercise for intermittent claudication.

Authors:  Risha Lane; Amy Harwood; Lorna Watson; Gillian C Leng
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

6.  The Impact of Peripheral Artery Disease (PAD) on Lower Limb Kinematics in Type 2 Diabetes Mellitus.

Authors:  Claire Saliba Thorne; Erica Bartolo; Alfred Gatt; Cynthia Formosa
Journal:  Rev Diabet Stud       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.